• In April 2026, CooperCompanies said it would report its second-quarter 2026 results on June 4 and host a conference call to review financial performance and corporate developments for its CooperVision and CooperSurgical units.
• Analyst expectations for profit growth and management’s earlier decision to raise full-year 2026 guidance highlight how demand for premium contact lenses and fertility-related offerings is shaping current sentiment toward the business.
• With management’s upgraded full-year guidance in focus, we’ll now consider how this update may influence CooperCompanies’ existing investment narrative.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Cooper Companies Investment Narrative Recap

To own CooperCompanies, you need to believe in steady, long-term demand for premium contact lenses and fertility-related products, and in management’s ability to convert that demand into consistent earnings. The upcoming June 4 earnings call, framed by raised full-year 2026 guidance, puts near term execution in focus, while the biggest risk remains whether MyDAY’s ramp and fertility-related offerings can offset pricing pressure and slower contact lens market growth; this latest announcement does not materially change that risk.

The most directly relevant recent update is management’s decision in early March to lift full-year 2026 revenue guidance to US$4.306 billion to US$4.346 billion, with organic growth of 4.5% to 5.5%. That guidance now serves as the key reference point for the June 4 results and call, where investors will be watching for confirmation that premium lenses and fertility-related products can sustain this outlook without being derailed by ongoing market softness or competition.

But while guidance is higher, investors should still be aware of how prolonged weakness in fertility and PARAGARD markets could...

Cooper Companies' narrative projects $4.9 billion revenue and $810.1 million earnings by 2029. This requires 5.4% yearly revenue growth and a $408.7 million earnings increase from $401.4 million today.

Uncover how Cooper Companies' forecasts yield a $91.07 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently see CooperCompanies’ fair value between US$43.49 and US$91.07, underscoring wide disagreement on upside. Against that backdrop, the raised 2026 guidance and dependence on MyDAY and fertility offerings give you several different performance paths to consider before deciding which narrative you find more convincing.

Explore 5 other fair value estimates on Cooper Companies - why the stock might be worth 31% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cooper Companies research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Cooper Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cooper Companies' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.